| 000 | 01569 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515222506.0 | ||
| 264 | 0 | _c20100525 | |
| 008 | 201005s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/WNL.0b013e3181dc1ae0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarriott, James J | |
| 245 | 0 | 0 |
_aEvidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. _h[electronic resource] |
| 260 |
_bNeurology _cMay 2010 |
||
| 300 |
_a1463-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCardiotoxins _xadverse effects |
| 650 | 0 | 4 | _aControlled Clinical Trials as Topic |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitoxantrone _xadverse effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aSystole _xdrug effects |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMiyasaki, Janis M | |
| 700 | 1 | _aGronseth, Gary | |
| 700 | 1 | _aO'Connor, Paul W | |
| 773 | 0 |
_tNeurology _gvol. 74 _gno. 18 _gp. 1463-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/WNL.0b013e3181dc1ae0 _zAvailable from publisher's website |
| 999 |
_c19796060 _d19796060 |
||